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ORIGINAL ARTICLE

BTK inhibition results in impaired CXCR4 chemokine
receptor surface expression, signaling and function in chronic
lymphocytic leukemia
S-S Chen1, BY Chang2, S Chang2, T Tong1, S Ham1, B Sherry3, JA Burger4, KR Rai1,5,6 and N Chiorazzi1,5,6
Bruton’s tyrosine kinase (BTK) is involved in the regulation of B-cell growth, migration and adhesion. The importance of BTK in cell
trafﬁcking is emphasized by the clonal contraction proceeded by lymphocytosis typical for the enzyme inhibitor, ibrutinib, in B-cell
malignancies, including chronic lymphocytic leukemia (CLL). Here, we investigated BTK regulation of leukemic B-cell trafﬁcking in a
mouse model of aggressive TCL1 CLL-like disease. Inhibiting BTK by ibrutinib reduced surface membrane (sm) levels of CXCR4 but
not CXCR5, CD49d and other adhesion/homing receptors. Decreased smCXCR4 levels resulted from blocking receptor signal
transduction, which in turn aborted cycling from and to the membrane. This resulted in rapid re-distribution of CLL cells from
spleens and lymph nodes into the circulation. CLL cells with impaired smCXCR4 from BTK inhibition failed to home to spleens.
These functional changes mainly resulted from inhibition of CXCR4 phosphorylation at Ser339, mediated directly by blocking BTK
enzymatic activity and indirectly by affecting the function of downstream targets PLCγ2 and PKCμ, and eventually synthesis of
PIM-1 and BTK itself. Our data identify CXCR4 as a key regulator in BTK-mediated CLL-cell retention and have elucidated a complex
set of not previously described mechanisms responsible for these effects.
Leukemia (2016) 30, 833–843; doi:10.1038/leu.2015.316

INTRODUCTION
Bruton’s tyrosine kinase (BTK) is a key player in B-cell antigen
receptor (BCR) signaling that regulates B-cell growth. In addition
to BCR signaling, BTK participates in signal transduction
through growth-factor receptors, Toll-like receptors, integrins and
G-protein-coupled receptors such as CXCR4 and CXCR5.1,2 Among
these, chemokine receptors and integrins modulate migration and
adhesion of B cells to a microenvironment that promotes cell
survival and proliferation.3,4
Growing evidence supports a potential role for BTK in the
trafﬁcking of leukemic B cells as well. In chronic lymphocytic
leukemia (CLL), CXCR4 (ref. 5) and the α4β1 integrin VLA-4
(CD49d/CD29)6 are markers of disease course and outcome.
Importantly, when the action of BTK is blocked, chemotaxis and
adhesion of CLL cells, induced by CXCL12, CXCL13 and VCAM-1,
are markedly reduced,7 as in normal B8 and pre-B9 cells.
Furthermore, BTK inhibition by ibrutinib induces rapid lymph
node (LN) and spleen shrinkage, believed to be due to impaired
adhesion; this is associated initially with lymphocytosis and
ultimately with lowered levels of leukemia cells in the blood of
patients with CLL and other B-cell malignancies.10,11 These actions
emphasize a key role for BTK in CLL-cell trafﬁcking and survival.
In normal B cells, BCR stimulation promotes CXCR4 internalization through Syk, BTK, PLCγ2 and PKC.12 PIM-1, ERK/MAPK cascade
activation3,13 and G-protein-coupled receptor kinases14 also
regulate CXCR4 receptor trafﬁcking and signaling. In addition,
BTK might also associate directly with CXCR4 by interacting with
the heterotrimeric G protein subunits Gα15 and Gβγ.16 All these

suggest direct or indirect regulation of CXCR4 expression and
function by BTK. Despite this information for normal B lymphocytes, evidence documenting the regulation of CLL B-cell
trafﬁcking and adhesion by BTK, and the breadth of mechanisms
responsible for these actions, has not been codiﬁed in vivo.
This might be especially important in CLL because the levels
of chemokine receptors and integrins on CLL cells are
heightened.7,17 Indeed, CLL cells have three- to fourfold higher
levels of smCXCR4 compared with normal B lymphocytes.4
This in vivo study strove to document the effects of BTK inhibition
and elucidate the mechanisms whereby BTK regulates B-cell
migration and homing/retention in lymphoid tissues. To do this,
we used ibrutinib, a BTK inhibitor with clinical beneﬁt in CLL patients
and a mouse model in which SCID mice are populated with murine
leukemia cells (TCL1-192) from a TCL-1-bearing mouse.18 TCL1-192
leukemic cells express an unmutated, clonal VH11/Vκ14 BCR and are
responsive to BCR crosslinking by endogenous phosphatidylcholine,
hence requiring BTK’s enzymatic activity. Adoptive transfer of these
leukemic cells into SCID animals leads to aggressive disease similar
to that observed in IGHV-unmutated CLL patients.19 Importantly, the
cellular responses to ibrutinib treatment in this mouse model are
very similar to CLL patients, including reduced tumor burden in
spleens and LNs and transient lymphocytosis that has not been
demonstrated in other animal models.17
We now show that ibrutinib treatment rapidly induces
continuous egress of CLL cells into the circulation and prevents
the return of cells to solid tissue sites, and that this is due not only
to impaired BCR signaling but also deregulated smCXCR4
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signaling and expression. Ibrutinib caused these changes in CXCR4
recycling (internalization and re-expression) by preventing phosphorylation at Ser339 and indirectly by altering the function of
downstream kinases PLCγ2, PKCμ and PIM-1 and eventually the
synthesis of BTK and PIM-1. Our results demonstrate for the ﬁrst
time a complex set of mechanisms responsible for ibrutinib’s
actions that contribute beneﬁcially for patients.
MATERIALS AND METHODS
Study design
Animal studies were performed in accordance with experimental protocols
approved by the Institutional Animal Care and Use Committee (IACUC) of
the Feinstein Institute for Medical Research. TCL1-192 cells that had been
transferred ﬁve times into 8-week-old female C.B-17 SCID (C.B-Igh-1b/IcrTacPrkdcscid) mice (Taconic Labs, Hudson, NY, USA) were used for all
experiments in this study. For short-term experiments, mice received
5 × 106 TCL1-192 cells by retro-orbital injection followed by ibrutinib (25 mg/
kg) or vehicle (1% HP beta-cyclodextrin) by oral gavage starting 2 weeks
later, when CLL cells were detectable in the circulation. This experiment was
carried out with 5 mice per treatment group per time point, and was
repeated for three different time points, 1, 4 and 24 h, to ensure adequately
powered sample sizes. For long-term treatment and survival assays, mice
received treatment daily in drinking water starting at 2 or 4 weeks post
tumor cell engraftment. Long-term treatment experiments were repeated
three times with 10 animals per treatment group per time point; all the longterm treated animals were killed 6 weeks post tumor cell engraftment, the
time when control mice appeared moribund. For survival experiments, there
was a total of 20 mice per treatment group. Four treatment groups were
followed for survival until mice appeared moribund or died. Sample sizes
were estimated based on our previous report that showed a signiﬁcant
delay in disease progression with ibrutinib treatment using this same
transfer model.17 Mice used for control and treatment groups were
randomly selected from a pool of recipient animals with no preestablished inclusion/exclusion criteria. Investigators were not blinded.

Flow cytometric analyses and 5-bromodeoxyuridine (BrdU)
incorporation assay
TCL1-192 cells were enumerated by incubation with ﬂuorescein isothiocyanate anti-CD45R/B220 (553087), Phycoerythrin anti-CD5 (553023), APCCXCR4 (558644), PerCPCy5.5-CXCR5 (560528), Phycoerythrin-CD49d
(553157; BD Biosciences, San Jose, CA, USA), PECy7 anti-CD39 (25-0391),
eFluor 450 anti-CD69 (48-0691), A700 anti-CD62L (56-0621), PECy7 antiCD5 (25-0051; eBioscience, San Diego, CA, USA), APC anti-S1PR1 (R&D,
Minneapolis, MN, USA, FAB7089A) and PECy7 anti-CD29 (BioLegend, San
Diego, CA, USA, 102222). BrdU incorporation assays were done following
the manufacture’s protocol (BD Biosciences). Flow cytometry data were
obtained with a BD LSRII machine (BD Biosciences), and analyzed with
FlowJo software (FlowJo, LLC, Ashland, OR, USA).

BTK occupancy and western blot analysis
BTK occupancy in splenocytes was measured as previously described.20
Protein expression was determined using standardized protocols with
monoclonal antibodies reactive with the following proteins: BTK
(clone 3533; Cell Signaling, Danvers, MA, USA; 1:1000), CXCR4 (clone 2074;
Abcam, Cambridge, UK; 1:500), phospho-CXCR4 (clone 74012, Abcam; 1:500),
PIM-1 (clone EP2645Y; Abcam; 1:10 000), GRK6 (clone D1A4, Cell Signaling;
1:1000), TCL1 (clone 4042; Cell Signaling; 1:1000) and β-actin (clone 8227;
Abcam; 1:5000). Phosphorylation states of multiple PKC isoforms were tested
by the phospho-PKC Antibody Sample Kit (Cell Signaling, catalog number
9921). Fluorescently stained protein bands were quantiﬁed using Molecular
Dynamics ImageQuant 5.2 software (GE Healthcare, Waukesha, WI, USA).

Ca2+ ﬂux analysis
TCL1-192 cells (5 × 106 cells/ml) were incubated in dye-free RPMI1640
medium supplemented with 5% FBS and 1 μM ﬂuorescent Ca++ indicator
Indo-1, acetoxymethyl ester (Invitrogen). 1 × 106 cells per tube were run for
30 s on LSRII to obtain a baseline reading, and then stimulated for 5 min by
5 μg/ml F(ab′)2 fragments of anti-IgM polyclonal antibodies or 200 ng/ml
CXCL12. Kinetic data were analyzed with FlowJo (BD Biosciences). The
intracellular Ca++ levels were calculated from the violet (440 nm) and green
(530 nm) emissions and plotted against the time parameter.
Leukemia (2016) 833 – 843

CXCR4 recycling assay
For ex vivo assays, TCL1-192 cells (1 × 106 cells/ml), collected from mice
previously treated with vehicle or ibrutinib, were seeded with or without
200 ng/ml CXCL12 for 2 h at 37 1C. After three washing steps with cold PBS
to remove CXCL12, cells were resuspended in medium and incubated at
37 1C for 40 min. For in vitro assays, TCL1-192 cells were resuspended in
medium containing 0.05% dimethylsulphoxide or ibrutinib at indicated
concentrations with CXCL12 stimulation as described.21 After CXCL12 removal,
dimethylsulphoxide or ibrutinib at the same concentration was added
back in suspension medium to study their effects on CXCR4 re-expression.

In vivo cell trafﬁcking assays
5 × 106 splenocytes collected from mice treated for 4 weeks were
adoptively transferred into another set of SCID mice pre-treated with
either vehicle or ibrutinib for 5 days. After transfer, mice continued to
receive the same treatments for 24 or 72 h. To analyze trafﬁcking of
CXCR4dimCD5br leukemic cells, 5 × 106 sorted CXCR4dimCD5br TCL1-192
cells collected from animals treated for 4 weeks were injected into new
recipients. Mice were killed 18 h later.

Statistics
Data represent means ± s.d. or s.e.m., as stated in ﬁgure legends. Statistical
signiﬁcance was calculated using Prism software version 6.0 (GraphPad,
La Jolla, CA, USA) from adequately powered sample sizes for two-tailed
tests using two-way ANOVA, unpaired Student’s t-test with Bonferroni
correction for multiple comparisons, nonparametric Mann–Whitney test, or
multiple t-test using the Holm–Sidak method, when applicable. Survival
curves were analyzed by log-rank test. Correlations were assessed with the
nonparametric Spearman correlation. Statistical signiﬁcance was deﬁned
as Po 0.05. All exact P-values are provided in the ﬁgure legends.

RESULTS
Functional BTK is needed to retain CLL cells in lymphoid tissues
We studied BTK’s involvement in CLL-cell retention in tissue niches
by treating mice with ibrutinib 2 weeks after TCL1-192 leukemia cell
injection, the time when CD19+CD5+ leukemic cells were detectable
in the spleen and blood.19 Because oral administration of ibrutinib
induces lymphocytosis within hours in CLL patients, in the ﬁrst set
of experiments we treated recipient mice once via gavage and
killed them 1, 4 and 24 h later. Although control mice had negligible
numbers of leukemic cells in the circulation, ibrutinib-treated
animals exhibited a signiﬁcant increase in circulating lymphocytes.
This lymphocytosis occurred as early as 1 h and peaked at 4 h after
the mice received ibrutinib (Figure 1a), indicating rapid uptake and
action of the drug. In support of this, within 1 h of oral treatment, all
BTK molecules in spleen-residing leukemia cells were occupied by
ibrutinib (Supplementary Figure 1A).
We then analyzed the composition of blood and spleen cell
populations in untreated and treated mice, analyzing the release
of resting and recently divided leukemic cells identiﬁed by
injecting BrdU at the time of treatment. After 1 h of BTK enzymatic
inhibition, signiﬁcantly higher numbers of BrdU+ TCL1-192 cells
were observed in circulation (Supplementary Figure 1B). Twentyfour hours after, animals receiving ibrutinib still had signiﬁcantly
more BrdU+ leukemia cells in the blood (vehicle vs ibrutinib:
3.4–3.7% vs 18.5–22.4%; Figure 1b). Of note, the percentage of
BrdU+ B cells in spleens very closely approximated the numbers in
the blood, suggesting ibrutinib promotes emigration of leukemic
cells into circulation proportional to that in tissues.
We next studied BTK-regulated CLL-cell retention in animals
treated for 4 weeks. At this time point (6 weeks post tumor
cell engraftment), most vehicle-treated mice were moribund;
however, mice receiving ibrutinib appeared healthy with signiﬁcantly lower absolute blood CLL-cell counts (Supplementary
Figure 2A), much less organomegaly, and reduced leukemic
cell inﬁltration in the spleens, liver and bone marrow
(Supplementary Figure 2B). We again measured proliferating CLL
cells by injecting BrdU 24 h before the end point of the study.
© 2016 Macmillan Publishers Limited
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Figure 1. Mobilization of lymphocytes into the peripheral circulation after BTK inhibition. (a) Signiﬁcant increases in TCL1-192 cell counts in PB
were observed in ibrutinib (Ibr)-treated animals 1 and 24 h after treatment via oral gavage (*Po0.05 by multiple t-test using the Holm–Sidak
method, n = 5 for each time point). The representative data shown were obtained from peripheral blood samples collected 4 h after the
treatment. (b) Increased numbers of BrdU+ leukemia cells were seen in PB 24 h (*P = 0.016, n = 5) after Ibr treatment. (c) TCL1-192 cell
proliferation as detected by BrdU incorporation in LN (n = 5) and SP (n = 8) was signiﬁcantly reduced after Ibr treatment for 4 weeks
(**P o0.01); however, percentage of BrdU+ B cells in PB was increased (***P o0.001, n = 10). P-values shown in b and c were calculated using
the Mann–Whitney nonparametric test; ‘NS’ indicates non-signiﬁcant P-values. All data plots represent the mean ± s.d. Representative
examples are shown on the top of each panel. PB, peripheral blood; SP, spleen; Veh, vehicle; wk, week.

Interestingly, although BTK inhibition abrogated the proliferation
of CLL cells in spleens and LNs, ibrutinib-treated animals still
displayed BrdU-labeled cells in the blood, despite their much
lower levels of circulating leukemia cells (Figure 1c). Notably, the
percentage of BrdU-labeled cells in the blood (6.7% ± 0.05) was
again higher than in control mice (~2%), while similar to those in
spleens (5.9% ± 0.08).
Thus, inhibition of BTK’s enzymatic activity rapidly and
continuously led to re-distribution of cells from tissues into the
© 2016 Macmillan Publishers Limited

circulation, highlighting the involvement of BTK in tissue
retention. This suppressed CLL-cell retention may minimize the
chance of malignant B cell to receive growth signaling in spleens
and LNs.
BTK inﬂuences smCXCR4 expression and signaling
We further dissected BTK-dependent mechanisms regulating
retention of CLL cells by studying the effect of ibrutinib treatment
Leukemia (2016) 833 – 843
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Figure 2. Rapidly reduced smCXCR4 levels after BTK inhibition. (a) Reduced smCXCR4 mean ﬂuorescence intensity (MFI) on leukemic cells
4 weeks (wks) after ibrutinib (Ibr) treatment reached levels similar to wild-type (WT) normal B cells (*P o0.05, **P o0.01, n = 5). Right panels
shown are representative ﬂow cytometry data. (b) SP cells collected 1h after Ibr treatment had signiﬁcantly reduced smCXCR4 MFI compared
with those from vehicle (Veh) group (*P = 0.03, n = 5); no difference was seen between Ibr-treated cells versus WT normal B cells (P = 0.23,
n = 5)). (c) Ca++ ﬂux results shown on the left are representative data from three experiments performed in triplicate. Normalized ratios of peak
to baseline Ca++ ﬂux in response to CXCL12 and anti-IgM pAbs are displayed on the right. These indicate signiﬁcantly reduced
Ca++ mobilization in SP-residing TCL1-192 cells after 1 h or 4 wks of Ibr treatment (*P = 0.028). All data plots represent the mean ± s.d. P-values
shown were calculated by Mann–Whitney test.

on speciﬁc molecular components known to control this process.
Among all the trafﬁcking/migration and adhesion molecules
assessed (Figure 2a and Supplementary Figure 3), including
CXCR4, CXCR5 and CD49d that have BTK in their signaling
cascade, as well as CD29, CD62L, CD39, CD69 and S1PR1, only
smCXCR4 was signiﬁcantly reduced levels on leukemic cells after
4 weeks of ibrutinib treatment; this was seen in both blood and
spleen samples (Figure 2a). Overexpressed smCXCR4 in CLL4 was
signiﬁcantly reduced in spleens within 1 h (Figure 2b). However,
notably, the total amount of CXCR4 protein remained unchanged
after ibrutinib treatment (Supplementary Figure 3), suggesting the
effect of BTK might be on receptor trafﬁcking within the cell.
Leukemia (2016) 833 – 843

We next determined if ibrutinib treatment impaired CXCR4
signal transduction potential of leukemia cells, rendering them
functionally inert. Splenocytes from mice were exposed for 5 min
to activate CXCR4 by native ligands (CXCL12), or the BCR by
surrogate ligands (anti-IgM pAbs). For short- (1 h) or long(4 weeks) term ibrutinib treatment in vivo blocked both BCR and
CXCR4 signaling pathways, as measured by Ca++ ﬂux (Figure 2c).
Collectively, these results indicate that smCXCR4 expression and
signaling are impaired in BTK-treated cells, indicating the dual role
of BTK in CXCR4 and BCR signaling, which together that contribute
to the support of leukemic cell growth in LNs and spleens
(Figure 1c).
© 2016 Macmillan Publishers Limited
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TCL1-192 cells from SP of mice treated for 1 h (n = 3) or 4 weeks (wks; n = 5) were seeded in culture medium (Med: RPMI1640+10% FBS) with or
without CXCL12. After 2 h incubation at 37 1C, cells from vehicle (Veh) but not ibrutinib (Ibr) groups had signiﬁcantly reduced smCXCR4
(**Po0.01). (b) Re-expression of smCXCR4 after CXCL12 removal was only seen in splenocytes collected from Veh mice (*P = 0.03), but not from
mice treated with Ibr for 4 wks (n = 5). (c) Signiﬁcantly higher smCXCR4 levels remained on 0.1 μM Ibr-treated cells than those on
dimethylsulphoxide (DMSO)-treated cells (*Po0.05, n = 4). Ibr-treated cells also failed to re-express smCXCR4 after CXCL12 removal. (d) TCL1-192
cells were exposed in vitro to DMSO or Ibr after CXCL12 washout (n = 4). Ibr treatment at ⩾ 0.1 μM signiﬁcantly reduced smCXCR4 re-expression
(*Po0.05). Left panels in c, d are representative histograms of smCXCR4 of two independent experiments performed in triplicate. P-values
shown were calculated by unpaired t-test using nonparametric Mann–Whitney test. ‘NS’ indicates non-signiﬁcant P-values. WO, wash out.

BTK regulates CXCR4 internalization and re-expression
Reduction of smCXCR4 levels without obvious changes in total
CXCR4 in BTK-inhibited cells suggested that CXCR4 recycling
(internalization and re-expression) had been altered and not that
enhanced CXCR4 degradation had occurred. Indeed, in vivo
ibrutinib treatment for 1 h and for 4 weeks completely prevented
smCXCR4 internalization stimulated by CXCL12 (Figure 3a).
In addition, reappearance of smCXCR4 after CXCL12 removal,
© 2016 Macmillan Publishers Limited

which occurred normally in the absence of ibrutinib, did not take
place in ibrutinib-treated cells (Figure 3b).
We next tested effects of ibrutinib on CXCR4 re-cycling in vitro
TCL1-192 cells were ﬁrst exposed to 0.1 μM ibrutinib for 2 h at
37 1C in the absence or presence of CXCL12. Again, after ligand
exposure, internalized smCXCR4 levels were signiﬁcantly reduced
by ibrutinib (Figure 3c). In addition, whereas CXCL12 removal
resulted in signiﬁcant re-expression of smCXCR4 on control cells,
Leukemia (2016) 833 – 843
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leukemia cells from animals treated for 4 weeks; levels of Ser339phosphorylated CXCR4 were considerably diminished, approximating levels observed in cells from wild-type mice. Notably, this
reduction correlated tightly with smCXCR4 expression (Figure 4a).
We next tested if BTK enzymatic activity/expression correlates
with smCXCR4 levels. To do this, we used the same dose of
ibrutinib to treat a group of mice for only 2 weeks starting at
4 weeks post TCL1-192 cell transfer. This treatment approach
delayed CLL progression but survival was shorter than the group
of mice treated for a total 4 weeks starting at week 2
(Supplementary Figure 4). Interestingly, analyzing leukemia cells
from mice treated with ibrutinib for either 2 or 4 weeks showed a
progressive fall in not only BTK enzymatic activity but also BTK
protein levels, which correlated directly with reduced smCXCR4
expression (Figure 4b and Supplementary Figure 5A).
Finally, we examined the levels and phosphorylation states of
kinases known to be responsible for CXCR4 phosphorylation,

the level of CXCR4 re-expression on ibrutinib-treated cells did not
change signiﬁcantly after ligand withdrawal (Figure 3c). Finally,
exposing TCL1-192 cells to ibrutinib (⩾0.1 μM) after CXCL12
withdrawal, signiﬁcantly reduced the re-expression levels of
smCXCR4 (Figure 3d).
Overall, the above data suggest BTK regulates smCXCR4
expression by modulating recycling of the receptor. In addition,
some receptors remain on the surface membrane (sm) because of
impeded internalization because of blocked ligand-mediated
signaling.
Mechanisms responsible for the regulation of CXCR4 recycling
by BTK
In CLL patient B cells, overexpression of smCXCR4 correlates with
hyper-phosphorylated Ser339 residues.21,22 Similar results were
also observed in TCL1-192 cells (Figure 4a). BTK inhibition blocked
CXCR4 phosphorylation, but not total CXCR4, in spleen-residing
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Figure 4. BTK inhibition blocks CXCL12-induced CXCR4 phosphorylation at Ser339. (a) In vivo ibrutinib (Ibr) treatment for 4 weeks (wks)
reduced levels of pCXCR4 but not total CXCR4 in TCL1-192 SP cells. N, normal SP B cells. (b) Ibr treatment for 4 or 2 wks reduced total BTK
levels in TCL1-192 SP cells. (a, b) Spearman correlation coefﬁcient of smCXCR4 expression (measured as mean ﬂuorescence intensity) versus
relative pCXCR4 protein levels (r = 0.88, P = 0.007) and BTK enzymatic activity assessed by BTK probe assay (r = 0.86, P = 0.003). (c) BTK
inhibition reduced levels of PIM-1 and p-PKCμ but not GRK6. (d) In vitro Ibr treatment at dosages ⩾ 0.1 μM for 2 h inhibited CXCL12-induced
CXCR4 phosphorylation (pCXCR4), but not total CXCR4. Phosphorylation of PKCμ (p-PKCμ) but not total PKCμ was inhibited in TCL1-192 cells
after 2 h of in vitro Ibr treatment at doses 40.1 μM. The quantiﬁed ratios of pCXCR4 and p-PKCμ are shown below the bands in c and d.
Veh, vehicle.
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not GRK6. The data also indicate that BTK is involved in a feedforward action that supports its own synthesis and that of PIM-1;
the latter is likely occurring because of the need for BTK to allow
BCR-mediated signaling, which is needed to foster production of
PIM-1 and BTK itself.

including GRK6, PIM-1 and PKC; the latter is an upstream regulator
of PIM-1 (ref. 23) and a downstream target of BCR signaling.24 BTK
inhibition signiﬁcantly reduced PIM-1, but not GRK6 protein levels
(Figure 4c). When testing the phosphorylation state of PKC
isoforms in splenocytes collected after 4 weeks of treatment, we
found BTK inhibition diminished levels of phosphorylated PKCμ
(p-PKCμ) that is constitutively associated with BTK25 and is
regulated by BCR/PLCγ2 signaling.26 Total levels of neither PKCμ
nor any other PKC isoforms tested were diminished by ibrutinib
treatment (Figure 4c and Supplementary Figure 5C).
Finally, we repeated these analyses on TCL1-192 cells treated
with ibrutinib in vitro Ibrutinib treatment (⩾0.1 μM) for only 2 h
reduced CXCL12-stimulated CXCR4 phosphorylation at Ser339
(Figure 4d). A reduction in p-PKCμ, but not other isoforms, was
also observed with ibrutinib exposure in vitro. Total protein levels
of CXCR4, PIM-1 and BTK remained unchanged in these short-term
ibrutinib-treated samples (Figure 4d and Supplementary Figure 5C).
Collectively, these data indicate that BTK regulates smCXCR4
signaling and recycling by allowing ligand-receptor interactions to
result in phosphorylation of CXC4 at Ser339 of its intracellular
domain. This in turn induces phosphorylation and activation of
PLCγ2 (as reported in our previous study17), PIM-1 and PKCμ, but

BTK regulates smCXCR4 (re)-expression and function in CLL B
lymphocytes
We next tested the effects of BTK on smCXCR4 re-expression and
the homing capacity of CLL B cells. First, we sorted the
CXCR4dimCD5br subpopulation of leukemic B cells that is enriched
in recently divided cells (Supplementary Figure 6), emigrating
from lymphoid tissues to the periphery.27 Even though the
CXCR4dimCD5br populations sorted from the blood of vehicle- and
ibrutinib-treated animals had similarly low smCXCR4 expression
(771 ± 46 vs 313 ± 28, Figure 5a), most vehicle-treated leukemic
cells were able to re-express smCXCR4 and migrate to the spleen
within 18 h of cell transfer. However, ibrutinib-treated leukemic
cells remained in the blood, with only a small number of cells able
to re-express smCXCR4 and migrate to spleens (Figures 5b and c).
We then studied if continuous ibrutinib treatment was required
to block BTK-mediated CLL-cell homing to tissue niches.
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Figure 5. BTK inhibition blocks smCXCR4 re-expression and CLL-cell homing. (a) 5x106 CXCR4dimCD5br cells sorted from PB of animals treated
for 4 weeks (wks; n = 4 per group) were injected into SCID animals; 18 h later mice were killed. The representative histogram plot and dot plots
of smCXCR4 indicate relatively similar smCXCR4 mean ﬂuorescence intensity in donor cells obtained and sorted from vehicle (Veh) and
ibrutinib (Ibr)-treated mice (*P o0.05). (b) Ibr-mobilized TCL1-192 cells migrating to SP exhibit persistently lower smCXCR4 than control cells
(P = 0.028, n = 4). (c) Signiﬁcantly higher numbers of Ibr-mobilized TCL1-192 cells remain in PB than SP (P = 0.03, n = 4). In contrast, the opposite
pattern is seen for Veh-treated cells with signiﬁcantly higher numbers of CLL cells in SP than PB (P = 0.03). Plots shown represent mean ± s.d.
Representative examples of B220+ cells obtained from PB 18 h post cell engraftment are shown on the left. P-values shown were calculated by
Mann–Whitney multiple t-test. ‘NS’ indicates non-signiﬁcant.
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Figure 6. Continuous treatment with ibrutinib (Ibr) is required to prevent smCXCR4 re-expression. (a) 5 × 106 SP TCL1-192 cells collected from
mice receiving vehicle (Veh) or Ibr for 4 weeks (wks) were injected into SCID mice previously treated daily for 5 days. All 24 SCID recipients
were treated continuously for 24 or 72 h. (b) At 24 h, tumor cells previously exposed to Ibr (white) had signiﬁcantly lower smCXCR4 compared
with those exposed to Veh (gray), regardless of whether they were subsequently transferred into Veh- or Ibr-treated mice (*Po 0.05,
**P o0.01; n = 3 per group). At 72 h, only Ibr-treated recipients had leukemic cells with reduced smCXCR4, regardless of the donor from which
the cells were taken. (c) At 24 h, mice that received leukemic cells previously exposed to Ibr had a higher number of CLL cells in PB, but lesser
number in SP, compared with those exposed to Veh, regardless of the treatment recipients received. At 72 h, only Ibr- but not Veh-treated
recipients had higher numbers of circulating cells in PB (*P o0.05, **P o0.01, ***P o0.001, n = 3 for each group). Plots are mean ± s.d.
P-values were calculated by unpaired parametric t-test. ‘NS’ indicates non-signiﬁcant P-values.

Splenocytes from mice treated for 4 weeks were injected into SCID
recipients receiving either vehicle or ibrutinib, and then the
recipient mice were killed 24 or 72 h later (Figure 6a). Splenocytes
from ibrutinib-treated mice that were transferred into vehicle-fed
animals maintained, for at least 24 h, lower smCXCR4 than those
transferred into ibrutinib-fed animals (Figure 6b, Top). However, at
72 h, smCXCR4 levels of both ibrutinib-treated and vehicle-treated
splenocytes were comparable in the ibrutinib-deﬁcient environment. Correspondingly, when cells from vehicle-treated animals
were placed in an ibrutinib-containing environment, smCXCR4
Leukemia (2016) 833 – 843

levels dropped progressively after 72 h (mean ﬂuorescence
intensity: 78.8 ± 2.9 vs 35.6 ± 7.7, P = 0.006; Figure 6b, bottom).
Consistent with reduced levels of smCXCR4, at 24 h, more ibrutinibtreated TCL1-192 cells remained in the blood of ibrutinib-fed
animals, whereas animals receiving vehicle-treated cells had more
leukemic B cells in their spleens, regardless of the type of treatment
recipient mice received (Figure 6c). After 72 h, ibrutinib-exposed
recipients had higher percentages of cells in their circulation.
Together, these data demonstrate that BTK is needed for
homing of leukemic B lymphocytes to lymphoid tissues
© 2016 Macmillan Publishers Limited
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Figure 7. Mechanisms whereby BTK phosphorylates CXCR4 and regulates CXCR4 signaling, recycling and B-cell tissue homing and retention.
(a) Inhibition of BTK (Figure 4b) and its downstream targets such as PLCγ2,17 PKCμ and PIM-1 (Figure 4c), diminishes CXCR4 phosphorylation,
recycling and consequently lowering smCXCR4 expression. (b) (Top) Hypothetical model of the lifecycle of CLL B cells. In solid tissues, CXCR4–
CXCL12 interactions enhance the tethering of CLL cells to stroma. Cellular activation, possibly by (auto)antigen stimulation, promotes higher CD5
expression, CXCR4 internalization and detachment of CLL cells from stroma. In circulation, recently divided CLL cells (CXCR4dimCD5bright) may
begin to re-express CXCR4. Eventually, CXCR4brightCD5dim CLL cells have the greatest chance of re-entering solid tissue and receiving pro-survival
signals. Those that do not re-enter die by survival signal-deprivation/exhaustion. (Bottom) BTK inhibition results in impaired CXCR4- and BCRsignaling and further lowered smCXCR4 levels to more effectively terminate stromal tethering. The majority of BTK-inhibited CLL cells are unable
to re-express sufﬁcient levels of functional smCXCR4 and thereby fail to re-enter niches, leading to greater survival signal-deprivation/exhaustion
and cell death. Through all these actions, BTK inhibition delays CLL disease progression. Ibr, ibrutinib; TLR, toll-like receptor.

and this requires ongoing synthesis of the enzyme. This is
consistent with the beneﬁcial effects of BTK inhibition in
leukemia patients10 and leukemia-bearing mice,17 and the
requirement that inhibition be maintained for therapeutic
efﬁcacy.28 By blocking the retention and homing of CLL cells
mediated at least by CXCR4, BTK inhibition delayed disease
progression and improved overall survival (Supplementary
Figure 4).
DISCUSSION
The Eμ-TCL1 mouse model resembles aggressive human CLL
based on the development of IGHV-unmutated leukemic clones.29
© 2016 Macmillan Publishers Limited

It also leads to the development of U-CLL-like subsets with
stereotyped IGHV-D-J rearrangements29 that are virtually identical
to sequences previously determined from murine B-1 cells and
murine autoantibodies to phosphatidylcholine, bromelain-treated
erythrocytes and nuclear components.30 The model used here
employs a U-CLL-like clone from a TCL1 Tg animal (TCL1-192) that
expresses a canonical anti-phosphatidylcholine BCR that binds
and responds to this autoantigen.19 Thus, this clone can serve as a
model of a stereotyped, autoantigen-reactive U-CLL subset
analogous to those expressing stereotyped IGHV-D-J rearrangements that react with autoantigens, resembling but not limited to
U-CLL subsets that use IGHV1-69 such as subset 6 that binds
myosin heavy chain IIA.31,32
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Using this model and a small-molecule inhibitor approach, we
have deﬁned the mechanisms responsible for BTK-mediated
CXCR4 expression and signaling in CLL (Figure 7a), thereby
providing in vivo evidence for BTK’s regulation of CLL B-cell
migration and homing (Figure 7b). Our novel ﬁndings include
documentation that:1 blocking BTK’s enzymatic activity, which
inhibits CXCR4-mediated signaling by preventing phosphorylation
of the receptor at Ser339, leads to a rapid and continuous release
of leukemia cells into the circulation, and this release associates
tightly with decreased smCXCR4 expression;2 BTK inhibition
indirectly alters the function of PKCμ, which is downstream of
CXCR4 signaling, contributing to a further impairment of CXCR4
phosphorylation and internalization/re-expression;3 inhibition of
BTK eventually results in decreased synthesis of PIM-1 and BTK
itself, enhancing the molecular and functional effects of enzyme
blockade; and4 diminished levels and function of smCXCR4 in vivo
prevent leukemic cells from re-entering protective niches, and
those actions require uninterrupted enzymatic inhibition.
BTK inhibition promoted release of leukemia cells into the
circulation, not only in ⩽ 1 h after ibrutinib administration, but also
after 4 weeks of treatment when circulating leukemic cell counts
were signiﬁcantly reduced (Figure 1). This continuous cell egress
included the most recently divided cells, the wellspring of clonal
evolution as new genomic abnormalities favoring disease
progression are introduced during DNA replication.33 Our results
agree with a recent study in CLL patients demonstrating that
ibrutinib releases Ki-67+ cells into the peripheral blood at
percentages similar to those in LNs.34 The rapid resolution of
lymphocytosis could be due to ibrutinib-promoted cell death.
However, this might be difﬁcult to measure as dying tumor cells
are quickly taken up by phagocytosis. Indeed, by analyzing
Annexin-V and 7-amino-actinomycin D expression on fresh
isolated cells, we were not able to detect Ibr-promoted cell death
in circulating or tissue-resident cells (Supplementary Figure 2C).
The rapid and continuous release of leukemia cells from
lymphoid tissues induced by ibrutinib’s occupation of available
BTK (Figure 1) resulted from two actions on CXCR4: selective
lowering of membrane receptor levels without affecting total
receptor amounts, and blocking CXCR4 signal transduction after
ligand binding (Figure 2). The reduction in smCXCR4 in ibrutinibtreated cells was relatively speciﬁc, as it was not found for other
BTK-regulated molecules that play a role in leukemic cell
migration and adhesion, including CXCR5 and CD49d
(Supplementary Figure 3). Our results are consistent with the
reduction of CXCR4 reported in ibrutinib-treated patients with
CLL7 and mantle cell lymphoma,35,36 and with the ﬁnding that
resistance to ibrutinib occurs in patients with Waldenstrom’s
macroglobulinemia with CXCR4 mutations.37
In the normal state, smCXCR4 is rapidly internalized and
re-expressed after ligand binding by a process dependent on
phosphorylation at Ser339.38 Here we found that BTK inhibition
rapidly and continuously impairs recycling of CXCR4 (Figure 3)
by blocking CXCL12-induced phosphorylation of CXCR4 at
Ser339 (Figure 4a). Inhibition of Ser339 phosphorylation also
resulted indirectly by preventing activation of downstream targets
such as PLCγ2 (shown previously in this model, ref. 17) and PKCμ
(Figures 4c and d), which is activated by chemokine stimulation.39
In addition, ongoing BTK inhibition eventually led to a reduction in
the protein levels of PIM-1, a target of BTK and PKC,23 and of BTK
itself, which requires BCR stimulation to regulate its synthesis.40
These data are consistent with the protein levels of BTK and PIM-1
positively correlating with smCXCR4 density in CLL and myeloma
cells.21,41
The transfer of BTK-inhibited cells into secondary recipients,
given either ibrutinib or vehicle control, helped elucidate the
consequences of impairing smCXCR4 expression, especially those
on leukemia cell trafﬁcking. For secondary recipients that
were continuously treated with ibrutinib, homing of leukemic
Leukemia (2016) 833 – 843

B lymphocytes to lymphoid tissues was aborted because of the
inability to re-synthesize BTK (Figures 5 and 6). In the absence of
newly produced BTK, CLL-cell homing remained impaired, making
leukemic cells susceptible to death by depriving sustaining inputs
through the BCR, CXCR4 and other trophic receptors. To our
knowledge, this is the ﬁrst in vivo demonstration of these
phenomena due to BTK blockade.
In addition, TCL1-192 cells remaining in tissues after BTK
inhibition displayed dysfunctional BCR and CXCR4 signaling
(Figure 2c) that could contribute to reduced leukemic cell growth
in spleens and LNs (Figure 1c). These actions of ibrutinib delayed
disease progression despite the aggressiveness of this leukemia
model (Supplementary Figure 4), although ultimately the animals
succumbed to the disease. This may be akin to CLL patients who
relapse when receiving ibrutinib mono-therapy.10 Because a small
percentage of dividing cells was still present in 4-week-treated
animals (Figure 1c), a ﬁnding that differs somewhat from the
apparent complete inhibition of leukemia cell proliferation
documented in previously untreated patients receiving
ibrutinib,42 some cells in the TCL1-192 population may have
developed compensatory mutations that subverted BTK blockade,
as seen in a minority of patients treated with ibrutinib.43 Indeed,
resistance might occur more frequently in TCL1-192 recipients
than in patients because of the higher number of proliferating
cells in this transfer system.19 Finally, the actions of ibrutinib on
CLL B-cell migration could also involve changes in the tumor
microenvironment. For example, in mantle cell lymphoma, a
reduction in serum levels of CCL4, CCL22 and CXCL13 occurs in
patients receiving ibrutinib.35
Altogether, using TCL1-192 cells that mimic human CLL and
ibrutinib, the therapeutically valuable BTK inhibitor, we have
uncovered a complex set of mechanisms responsible for the
regulation of CXCR4 expression and function. Considering the
need of human CLL cells for ancillary survival and growth signals,
inhibition of BTK function would lead to a loss of tumor volume by
preventing replenishment after spontaneous or drug-induced
death, and by subverting leukemia cell retention in and homing
back to sustaining tissue niches (Figure 7). The dual action of
ibrutinib on CXCR4 as well as BCR function delays disease
progression and prolongs survival.
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